ANRO

Alto Neuroscience Inc

Add to Watchlist

Advanced Chart

3.050

-0.02(-0.651%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.120

Open

3.050

VWAP

3.05

Vol

220.95K

Mkt Cap

83.25M

Low

3.030

Amount

674.18K

EV/EBITDA(TTM)

Total Shares

27.07M

-56.49M

EV/OCF(TTM)

P/S(TTM)

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

7 Analyst Rating

240.98% Upside

Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 10.40 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

240.98% Upside

Current: 3.050

Low

4.00

Averages

10.40

High

15.00

240.98% Upside

Current: 3.050

Low

4.00

Averages

10.40

High

15.00

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Initiates

$10

2025-04-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2025-04-07

Initiates

Strong Buy

Reason

Jones Trading

Justin Walsh

Strong Buy

Initiates

$18

2024-12-16

Reason

Jones Trading

Justin Walsh

Price Target

$18

2024-12-16

Initiates

Strong Buy

Reason

Stifel

Paul Matteis

Strong Buy

Maintains

$32 → $10

2024-11-13

Reason

Stifel

Paul Matteis

Price Target

$32 → $10

2024-11-13

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Alto Neuroscience to $10 from $32 and keeps a Buy rating on the shares. The firm notes its lowered target reflects the failure of ALTO-100, but it continues to see the stock's risk/reward as "compelling," especially as it relates to ALTO-300, which employs a biomarker strategy in an attempt to enrich for better efficacy with agomelatine, an approved antidepressant in Europe.

Wedbush

Laura Chico

Buy

Hold

Downgrades

$29 → $4

2024-10-23

Reason

Wedbush

Laura Chico

Price Target

$29 → $4

2024-10-23

Downgrades

Buy

Hold

Reason

Baird

Brian Skorney

Buy

Maintains

$32 → $10

2024-10-23

Reason

Baird

Brian Skorney

Price Target

$32 → $10

2024-10-23

Maintains

Buy

Reason

Wedbush

Laura Chico

Buy

Reiterates

$29

2024-09-10

Reason

Wedbush

Laura Chico

Price Target

$29

2024-09-10

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alto Neuroscience Inc (ANRO.N) is -1.19, compared to its 5-year average forward P/E of -3.07. For a more detailed relative valuation and DCF analysis to assess Alto Neuroscience Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.07

Current PE

-1.19

Overvalued PE

-1.11

Undervalued PE

-5.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.18

Current EV/EBITDA

0.59

Overvalued EV/EBITDA

0.54

Undervalued EV/EBITDA

-0.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

+8.97%

-15.68M

Operating Profit

FY2025Q1

YoY :

+13.06%

-15.17M

Net Income after Tax

FY2025Q1

YoY :

-26.32%

-0.56

EPS - Diluted

FY2025Q1

YoY :

+47.94%

-16.58M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 159.2% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

457.8K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

565.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ANRO News & Events

Events Timeline

2025-06-30 (ET)

2025-06-30

09:30:24

Alto Neuroscience highlights study results guiding ALTO-207 development

2025-06-26 (ET)

2025-06-26

07:52:26

Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results

2025-06-03 (ET)

2025-06-03

06:07:06

Alto Neuroscience acquires dopamine agonist combination candidate

News

7.0

09:00 AMPRnewswire

Class Action Filed Against Alto Neuroscience, Inc. (ANRO) Seeking Recovery for Investors - Contact Levi & Korsinsky

7.0

02:12 AMGlobenewswire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

7.0

07-31Globenewswire

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO